Condition: Schizophrenia · Schizoaffective Disorder · Bipolar 1 Disorder · Sponsor: University of Texas Southwestern Medical Center
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.
This description comes directly from the study's public registry record.
Asha Philip · 214-648-5276 · asha.philip@utsouthwestern.edu
Emily McNeil · 214-648-1683 · emily.mcneil@utsouthwestern.edu
Always discuss trial participation with your own doctor first.
| Hartford Healthcare | Hartford, Connecticut, United States | Recruiting |
| University of Georgia | Athens, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04580134